Boston Scientifics Pivotal Trial Shows Over 93 Success Rate for Device ONCO Q1 2025 Earnings Positive EPS Reported Amid Limited Data ImmunityBio Gains Momentum as FDA Accepts ANKTIVA sBLA for Bladder Cancer Expansion